Hospital
Ascension Se Wisconsin Hospital, INC
Ascension Se Wisconsin Hospital, INC was paid $94.32M by Medicaid between Jan 2018 and Dec 2024, across 532 billing codes. Its largest line is 99283, emergency room visit (moderate) — 10% of everything it billed.
33Billing provider infoASCENSION SE WISCONSIN HOSPITAL, INC
MILWAUKEE, WI 53210
MILWAUKEE, WI 53210
33aNPI1427007384assigned 05/09/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$94.32M
24GClaims3,382,182
24DCodes billed532
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#2 of 60
Median peer was paid$2.90M
This provider vs. median32×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MCCULLOUGH, MICHAEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 505,830 | $15.53M | |
| 2019 | 502,067 | $14.87M | |
| 2020 | 430,453 | $12.33M | |
| 2021 | 521,674 | $13.88M | |
| 2022 | 477,251 | $12.88M | |
| 2023 | 543,851 | $13.70M | |
| 2024incomplete | 401,056 | $11.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 150,193 | 131,609 | $9.90M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.7% | 120,814 | 106,095 | $7.25M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.9% | 45,316 | 36,073 | $6.55M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 4.1% | 57,437 | 40,813 | $3.88M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.0% | 66,690 | 57,954 | $3.75M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.9% | 95,526 | 27,009 | $3.65M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.7% | 47,478 | 42,701 | $2.54M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.3% | 56,882 | 50,837 | $2.22M |
| 80053 | Comprehensive metabolic panel | 2.2% | 95,478 | 80,470 | $2.10M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.0% | 56,881 | 50,843 | $1.91M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.7% | 17,255 | 16,024 | $1.62M |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.7% | 49,571 | 44,313 | $1.58M |
520 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 21,953 | $1.52M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 29,636 | $1.47M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 17,061 | $1.46M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 18,080 | $1.43M |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.4% | 25,427 | $1.29M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.3% | 13,016 | $1.24M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.3% | 22,295 | $1.18M |
| 59025 | Fetal non-stress test | 1.2% | 16,228 | $1.17M |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 53,675 | $1.11M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 13,606 | $1.09M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.2% | 48,512 | $1.09M |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.1% | 21,641 | $1.05M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 18,733 | $924K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 13,151 | $918K |
| 81001 | <1% | 66,210 | $908K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 11,659 | $866K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 124,938 | $821K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 15,752 | $791K |
| 81025 | <1% | 69,102 | $741K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 6,470 | $723K |
| G0378 | Hospital observation service, per hour | <1% | 16,082 | $699K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 6,264 | $645K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 3,220 | $604K |
| 82962 | <1% | 38,881 | $547K | |
| 87081 | <1% | 21,975 | $514K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 11,442 | $480K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 2,661 | $466K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 2,607 | $438K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 15,494 | $413K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 2,013 | $412K |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 1,176 | $410K |
| 81003 | <1% | 39,292 | $409K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 809 | $389K |
| 84484 | <1% | 37,235 | $369K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,405 | $368K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 20,955 | $354K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,760 | $344K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 13,971 | $332K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 6,562 | $331K |
| 20610 | <1% | 3,570 | $323K | |
| 12001 | <1% | 3,457 | $309K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 29,211 | $303K |
| 97162 | <1% | 7,327 | $297K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 9,986 | $283K |
| 84702 | <1% | 12,145 | $281K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,220 | $272K |
| 76801 | <1% | 8,290 | $258K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 5,858 | $251K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,950 | $243K |
| 76830 | Ultrasound, transvaginal | <1% | 5,762 | $240K |
| 83880 | <1% | 9,789 | $235K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 11,458 | $235K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 17,368 | $233K |
| 12011 | <1% | 2,440 | $231K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 4,684 | $224K |
| 10060 | <1% | 2,504 | $218K | |
| 87634 | <1% | 3,616 | $218K | |
| 85027 | <1% | 32,763 | $208K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,305 | $203K |
| 12002 | <1% | 2,332 | $200K | |
| 80061 | Lipid panel | <1% | 15,130 | $191K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 26,776 | $188K |
| 83690 | <1% | 32,637 | $188K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 5,210 | $187K |
| 82728 | <1% | 9,351 | $187K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 3,899 | $184K |
| 86780 | <1% | 16,766 | $179K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 10,511 | $177K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 6,696 | $167K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 17,948 | $160K |
| 70496 | <1% | 1,989 | $160K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,725 | $159K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,128 | $157K |
| 87653 | <1% | 4,520 | $155K | |
| 93971 | <1% | 4,572 | $154K | |
| 97161 | <1% | 3,797 | $151K | |
| 84112 | <1% | 1,737 | $147K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 42,275 | $145K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,206 | $144K |
| 70498 | <1% | 2,018 | $141K | |
| 76642 | <1% | 3,779 | $141K | |
| 93017 | <1% | 3,064 | $139K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 4,151 | $135K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,308 | $130K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 8,087 | $129K |
| 82950 | <1% | 5,663 | $121K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,853 | $119K |
| 82607 | <1% | 7,278 | $116K | |
| 97163 | <1% | 2,988 | $115K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 8,590 | $115K |
| 96367 | <1% | 2,081 | $115K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,100 | $110K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,405 | $107K |
| 70486 | <1% | 2,699 | $104K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 1,968 | $103K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,468 | $102K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 511 | $101K |
| 97166 | <1% | 2,680 | $99K | |
| 86762 | <1% | 7,045 | $98K | |
| 36430 | <1% | 835 | $96K | |
| 93970 | <1% | 1,767 | $95K | |
| 82565 | <1% | 6,524 | $92K | |
| 97116 | <1% | 5,668 | $92K | |
| 87210 | <1% | 11,281 | $90K | |
| 73630 | <1% | 11,204 | $88K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,309 | $87K |
| 83605 | <1% | 9,532 | $85K | |
| 86850 | <1% | 13,702 | $85K | |
| 83735 | <1% | 16,272 | $84K | |
| 93356 | <1% | 833 | $84K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 11,678 | $84K |
| 90715 | <1% | 10,426 | $83K | |
| 80143 | <1% | 5,334 | $80K | |
| 76536 | <1% | 1,764 | $78K | |
| 87340 | <1% | 8,184 | $76K | |
| 29125 | <1% | 1,860 | $72K | |
| 87077 | <1% | 6,562 | $72K | |
| 87186 | <1% | 9,080 | $70K | |
| 76770 | <1% | 1,375 | $70K | |
| 86803 | <1% | 5,851 | $69K | |
| 94060 | <1% | 2,869 | $69K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 1,705 | $69K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,171 | $68K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 1,958 | $68K |
| 85610 | <1% | 14,830 | $66K | |
| 83655 | <1% | 3,027 | $61K | |
| 80179 | <1% | 5,296 | $61K | |
| 83970 | <1% | 2,047 | $60K | |
| 77066 | Tomosynthesis, mammo | <1% | 2,466 | $60K |
| 86481 | <1% | 741 | $59K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,694 | $59K |
| 10061 | <1% | 759 | $58K | |
| 84703 | <1% | 7,519 | $58K | |
| 85379 | <1% | 7,164 | $56K | |
| 72100 | <1% | 6,656 | $56K | |
| 71250 | <1% | 1,633 | $56K | |
| T1016 | Case management, each 15 minutes | <1% | 12,073 | $55K |
| 94660 | <1% | 852 | $53K | |
| 77065 | Tomosynthesis, mammo | <1% | 2,410 | $52K |
| 80074 | <1% | 1,112 | $52K | |
| 87040 | <1% | 4,216 | $51K | |
| 90670 | <1% | 3,266 | $49K | |
| 97165 | <1% | 1,629 | $49K | |
| 36475 | <1% | 82 | $49K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 967 | $48K |
| J1726 | Injection, hydroxyprogesterone caproate, (makena), 10 mg | <1% | 1,181 | $48K |
| 97035 | <1% | 4,221 | $48K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 387 | $47K |
| 82746 | <1% | 3,952 | $47K | |
| 80171 | <1% | 1,907 | $46K | |
| 94729 | <1% | 2,414 | $46K | |
| 72141 | <1% | 628 | $45K | |
| 87147 | <1% | 8,113 | $44K | |
| 80076 | <1% | 4,674 | $44K | |
| 86901 | <1% | 15,265 | $44K | |
| 81511 | <1% | 317 | $44K | |
| 87070 | <1% | 2,734 | $43K | |
| 86900 | <1% | 13,720 | $42K | |
| 76820 | <1% | 4,041 | $42K | |
| 70491 | <1% | 568 | $41K | |
| 83020 | <1% | 3,173 | $41K | |
| 90651 | <1% | 1,077 | $40K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,395 | $38K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 688 | $38K |
| 73030 | <1% | 8,740 | $38K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 109 | $38K |
| 82570 | <1% | 6,202 | $37K | |
| 82550 | <1% | 6,517 | $37K | |
| 86703 | <1% | 2,101 | $36K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 62,917 | $36K |
| 73562 | <1% | 8,264 | $35K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 850 | $35K |
| 87529 | <1% | 616 | $34K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,990 | $34K |
| 85730 | <1% | 7,731 | $33K | |
| 76870 | <1% | 887 | $32K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 54,535 | $32K |
| 81002 | <1% | 1,229 | $32K | |
| 84153 | <1% | 1,528 | $30K | |
| 93458 | <1% | 57 | $30K | |
| 83550 | <1% | 4,408 | $30K | |
| 84439 | <1% | 2,972 | $29K | |
| 90686 | <1% | 4,459 | $29K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 933 | $28K |
| G0008 | Administration of influenza virus vaccine | <1% | 6,048 | $28K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 3,985 | $28K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 329 | $28K |
| 83540 | <1% | 5,068 | $28K | |
| 82800 | <1% | 3,127 | $27K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 10,477 | $27K |
| 73130 | <1% | 8,846 | $26K | |
| 74018 | <1% | 4,232 | $26K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 471 | $25K |
| 85007 | <1% | 7,998 | $25K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 560 | $25K |
| 84550 | <1% | 5,544 | $25K | |
| 0042T | <1% | 447 | $24K | |
| 0002A | <1% | 1,641 | $24K | |
| 86787 | <1% | 3,491 | $24K | |
| 73610 | <1% | 8,823 | $23K | |
| 73560 | <1% | 4,149 | $23K | |
| 83615 | <1% | 4,221 | $23K | |
| 85014 | <1% | 4,347 | $22K | |
| 0001A | <1% | 1,789 | $22K | |
| 73502 | <1% | 4,627 | $21K | |
| 29515 | <1% | 413 | $21K | |
| 71045 | Radiologic examination, chest; single view | <1% | 44,916 | $21K |
| 93922 | <1% | 565 | $20K | |
| 77062 | <1% | 1,759 | $20K | |
| 72040 | <1% | 2,373 | $20K | |
| 82010 | <1% | 2,888 | $19K | |
| 87088 | <1% | 2,504 | $19K | |
| 84450 | <1% | 3,763 | $19K | |
| 82951 | <1% | 384 | $19K | |
| 84460 | <1% | 3,785 | $18K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 350 | $18K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 116 | $18K |
| 73221 | <1% | 288 | $17K | |
| 97803 | <1% | 1,460 | $17K | |
| 95816 | <1% | 164 | $17K | |
| 82077 | <1% | 1,722 | $17K | |
| 97113 | <1% | 223 | $17K | |
| 87075 | <1% | 2,142 | $16K | |
| 82043 | <1% | 1,909 | $15K | |
| 86480 | <1% | 201 | $15K | |
| 82553 | <1% | 2,786 | $15K | |
| 12013 | <1% | 175 | $15K | |
| 84163 | <1% | 341 | $14K | |
| 77080 | <1% | 344 | $13K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,856 | $13K |
| 86140 | <1% | 3,356 | $13K | |
| 77061 | <1% | 1,148 | $13K | |
| 64400 | <1% | 103 | $13K | |
| 73110 | <1% | 4,786 | $12K | |
| 82105 | <1% | 327 | $12K | |
| 84156 | <1% | 3,302 | $12K | |
| 97533 | <1% | 509 | $11K | |
| 84520 | <1% | 3,077 | $11K | |
| 80164 | <1% | 702 | $11K | |
| 85018 | <1% | 4,728 | $10K | |
| 82803 | <1% | 558 | $10K | |
| 94726 | <1% | 1,531 | $10K | |
| 85049 | <1% | 2,405 | $10K | |
| 85652 | <1% | 2,924 | $10K | |
| 87205 | <1% | 2,679 | $9K | |
| H1002 | Prenatal care, at risk enhanced service; care coordination | <1% | 388 | $9K |
| G0009 | Administration of pneumococcal vaccine | <1% | 3,961 | $9K |
| 84132 | <1% | 1,797 | $9K | |
| H1000 | Prenatal care, at-risk assessment | <1% | 430 | $9K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 719 | $9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 703 | $8K |
| 84100 | <1% | 2,459 | $8K | |
| 72070 | <1% | 1,576 | $8K | |
| 99406 | <1% | 1,133 | $8K | |
| 86923 | <1% | 648 | $8K | |
| 96368 | <1% | 135 | $8K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 243 | $8K |
| 97802 | <1% | 770 | $8K | |
| 90710 | <1% | 1,373 | $8K | |
| 19083 | <1% | 28 | $8K | |
| 29105 | <1% | 67 | $8K | |
| 90648 | <1% | 1,364 | $7K | |
| 73564 | <1% | 1,344 | $7K | |
| 96415 | <1% | 94 | $7K | |
| 92523 | <1% | 142 | $7K | |
| 87015 | <1% | 31 | $7K | |
| 31500 | <1% | 35 | $7K | |
| 76813 | <1% | 400 | $6K | |
| 86038 | <1% | 581 | $6K | |
| 73140 | <1% | 3,977 | $6K | |
| 99385 | <1% | 207 | $6K | |
| 90633 | <1% | 1,525 | $6K | |
| 97012 | <1% | 330 | $6K | |
| 90698 | <1% | 1,731 | $6K | |
| 90674 | <1% | 638 | $6K | |
| 84704 | <1% | 341 | $6K | |
| 88307 | <1% | 946 | $6K | |
| 73080 | <1% | 2,297 | $6K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 10,844 | $5K |
| 73565 | <1% | 1,945 | $5K | |
| 82140 | <1% | 592 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 38,526 | $5K |
| 93798 | <1% | 64 | $5K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 531 | $5K |
| 80177 | <1% | 413 | $5K | |
| 43249 | <1% | 32 | $5K | |
| 94618 | <1% | 150 | $5K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 14 | $5K |
| 73590 | <1% | 2,819 | $5K | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 1,747 | $4K |
| 87252 | <1% | 108 | $4K | |
| 90681 | <1% | 1,409 | $4K | |
| 82247 | <1% | 163 | $4K | |
| 77049 | <1% | 29 | $4K | |
| 97167 | <1% | 109 | $4K | |
| 90474 | <1% | 1,298 | $4K | |
| 87631 | <1% | 30 | $4K | |
| 87207 | <1% | 71 | $4K | |
| 76942 | <1% | 363 | $4K | |
| 86593 | <1% | 228 | $3K | |
| 90656 | <1% | 436 | $3K | |
| 88738 | <1% | 255 | $3K | |
| 74183 | <1% | 41 | $3K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 15 | $3K |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 130 | $3K |
| 74178 | <1% | 42 | $3K | |
| 99381 | <1% | 44 | $3K | |
| 73090 | <1% | 2,117 | $3K | |
| 86706 | <1% | 329 | $3K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 67 | $3K |
| 73552 | <1% | 1,180 | $3K | |
| 87505 | <1% | 26 | $3K | |
| 99188 | <1% | 56 | $3K | |
| 69209 | <1% | 467 | $3K | |
| 91300 | <1% | 784 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 63,444 | $2K |
| 90723 | <1% | 1,333 | $2K | |
| 93880 | <1% | 38 | $2K | |
| 71101 | <1% | 2,713 | $2K | |
| 73060 | <1% | 914 | $2K | |
| 90677 | <1% | 175 | $2K | |
| 11981 | <1% | 32 | $2K | |
| 71271 | <1% | 26 | $2K | |
| 86235 | <1% | 29 | $2K | |
| 90837 | Psychotherapy session, about an hour | <1% | 67 | $2K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 327 | $2K |
| 73660 | <1% | 591 | $2K | |
| 87449 | <1% | 165 | $2K | |
| 86431 | <1% | 288 | $2K | |
| 74019 | <1% | 2,100 | $1K | |
| 93308 | <1% | 13 | $1K | |
| 87522 | Neg quan hep c or qual rna | <1% | 31 | $1K |
| 80185 | <1% | 106 | $1K | |
| 36591 | <1% | 1,065 | $1K | |
| 86580 | <1% | 91 | $1K | |
| 31720 | <1% | 50 | $1K | |
| 96376 | <1% | 9,234 | $1K | |
| 73120 | <1% | 184 | $1K | |
| 83516 | <1% | 80 | $1K | |
| 76818 | <1% | 66 | $1K | |
| 72170 | <1% | 922 | $1K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 2,316 | $1K |
| 84481 | <1% | 99 | $1K | |
| 99386 | <1% | 72 | $1K | |
| 73700 | <1% | 30 | $1K | |
| 73620 | <1% | 188 | $1K | |
| 82248 | <1% | 273 | $1K | |
| 90734 | <1% | 131 | $1K | |
| 94150 | <1% | 2,404 | $972.18 | |
| 84146 | <1% | 62 | $968.87 | |
| 94727 | <1% | 300 | $927.21 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,181 | $925.83 |
| 97018 | <1% | 65 | $873.29 | |
| 95886 | <1% | 15 | $871.53 | |
| 84165 | <1% | 136 | $855.17 | |
| 90678 | <1% | 151 | $838.20 | |
| 85046 | <1% | 174 | $833.21 | |
| 83001 | <1% | 62 | $799.35 | |
| 84145 | <1% | 44 | $792.61 | |
| 86704 | <1% | 92 | $792.15 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,930 | $777.31 |
| 73070 | <1% | 91 | $772.82 | |
| 99292 | <1% | 1,900 | $745.55 | |
| 82952 | <1% | 176 | $731.54 | |
| 99205 | Prolong outpt/office vis | <1% | 15 | $683.61 |
| 90744 | <1% | 300 | $681.65 | |
| 86200 | <1% | 55 | $679.77 | |
| J2704 | Injection, propofol, 10 mg | <1% | 20,616 | $673.94 |
| 90685 | <1% | 256 | $622.77 | |
| 90750 | <1% | 47 | $614.85 | |
| H1003 | Prenatal care, at-risk enhanced service; education | <1% | 109 | $607.69 |
| 92610 | <1% | 17 | $585.72 | |
| 94762 | <1% | 3,735 | $575.05 | |
| 85660 | <1% | 13 | $564.50 | |
| 72050 | <1% | 28 | $542.87 | |
| 90680 | <1% | 45 | $539.94 | |
| 97602 | <1% | 32 | $516.16 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,322 | $493.44 |
| 93321 | <1% | 12 | $483.99 | |
| 87110 | <1% | 30 | $467.18 | |
| 95806 | <1% | 12 | $452.44 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 508 | $442.23 |
| 70480 | <1% | 14 | $441.73 | |
| 86308 | <1% | 81 | $438.20 | |
| 85045 | <1% | 125 | $415.41 | |
| 88360 | <1% | 13 | $384.67 | |
| 90696 | <1% | 163 | $376.02 | |
| 97022 | <1% | 44 | $364.94 | |
| 80050 | General health panel | <1% | 115 | $363.57 |
| 96402 | <1% | 14 | $348.35 | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 46 | $345.97 |
| 90688 | <1% | 71 | $334.40 | |
| 87563 | <1% | 14 | $312.69 | |
| 76828 | <1% | 41 | $303.40 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 20 | $287.96 |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | <1% | 16 | $287.45 |
| 88342 | <1% | 2,593 | $282.28 | |
| 82805 | <1% | 15 | $279.37 | |
| 86039 | <1% | 31 | $239.06 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 10,428 | $193.57 |
| 82375 | <1% | 17 | $185.66 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 7,305 | $183.01 |
| G0010 | Administration of hepatitis b vaccine | <1% | 274 | $181.72 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 33,604 | $179.31 |
| 84403 | <1% | 13 | $175.74 | |
| 76825 | <1% | 18 | $175.20 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 33,078 | $168.60 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 4,755 | $166.15 |
| 96401 | <1% | 42 | $164.25 | |
| 51701 | <1% | 84 | $151.64 | |
| 88304 | <1% | 1,668 | $150.96 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 6,821 | $144.81 |
| 87140 | <1% | 30 | $130.86 | |
| 86870 | <1% | 41 | $127.76 | |
| 90732 | <1% | 28 | $112.54 | |
| 93325 | <1% | 12 | $112.52 | |
| 88341 | <1% | 216 | $107.79 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 683 | $103.04 |
| 85384 | <1% | 17 | $100.40 | |
| 72220 | <1% | 27 | $97.34 | |
| 76827 | <1% | 18 | $87.65 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 10,901 | $85.33 |
| 82378 | <1% | 15 | $70.45 | |
| 51798 | <1% | 178 | $68.94 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,159 | $65.50 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,773 | $59.91 |
| 82947 | <1% | 15 | $57.00 | |
| 99152 | <1% | 1,401 | $55.53 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 11,671 | $48.21 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 10,172 | $42.28 |
| 98960 | <1% | 47 | $39.54 | |
| 81015 | <1% | 19 | $37.99 | |
| 88300 | <1% | 140 | $32.43 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 3,600 | $29.92 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,791 | $28.91 |
| 0011A | <1% | 62 | $26.51 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 642 | $25.92 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 3,141 | $19.39 |
| 70360 | <1% | 106 | $18.69 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 284 | $18.60 |
| 91305 | <1% | 33 | $18.58 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15,738 | $17.30 |
| 99153 | Mod sedat endo service >5yrs | <1% | 859 | $15.66 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,219 | $13.62 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 2,037 | $13.37 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,097 | $11.53 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 5,674 | $11.34 |
| 90662 | <1% | 15 | $9.56 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,451 | $9.37 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 10,453 | $8.35 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 322 | $7.82 |
| 94760 | <1% | 3,385 | $4.04 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 907 | $4.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,570 | $1.09 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 586 | $0.86 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 252 | $0.74 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,320 | $0.42 |
| A4550 | Surgical trays | <1% | 238 | $0.31 |
| A9270 | Non-covered item or service | 0% | 27,990 | $0.00 |
| J3490 | Unclassified drugs | 0% | 820 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 255 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 367 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 471 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 146 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 877 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 349 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 137 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 656 | $0.00 |
| C1769 | Guide wire | 0% | 1,168 | $0.00 |
| 0012A | 0% | 32 | $0.00 | |
| A4364 | Adhesive, liquid or equal, any type, per oz | 0% | 37 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 274 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 364 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 41 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 186 | $0.00 |
| 97010 | 0% | 227 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 63 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 43 | $0.00 |
| 74022 | 0% | 25 | $0.00 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 14 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 55 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 14 | $0.00 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | 0% | 55 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 62 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 40 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 112 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 132 | $0.00 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 0% | 107 | $0.00 |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | 0% | 14 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 396 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 1,474 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 695 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 88 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 47 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 3,662 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 1,048 | $0.00 |
| J1729 | Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg | 0% | 780 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 686 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 299 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 801 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 30 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 82 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 129 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 336 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 291 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 645 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 58 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 237 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 220 | $0.00 |
| 88312 | 0% | 114 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 129 | $0.00 |
| 94681 | 0% | 14 | $0.00 | |
| 73000 | 0% | 16 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 54 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 120 | $0.00 |
| 94690 | 0% | 82 | $0.00 | |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 15 | $0.00 |
| 94664 | 0% | 12 | $0.00 | |
| 16020 | 0% | 12 | $0.00 | |
| 51702 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCULLOUGH, MICHAEL (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.